Intensive Crisis Intervention
Launched by JENNIFER HUGHES · Jun 21, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help young people who are going through a serious mental health crisis, especially those having thoughts of suicide or who have tried to harm themselves. The goal is to see if a shorter, focused treatment can be as effective as staying in the hospital for a longer time. This study takes place at Nationwide Children's Hospital and is currently looking for participants.
Young people between the ages of 12 and 17 who come to the hospital with suicidal thoughts or behaviors may be eligible to join, as long as they and their legal guardian agree to participate. To be part of the study, the young person needs to have a certain level of risk based on a questionnaire and must live with a caregiver who can give permission for the study. Participants will receive care either through a brief, intensive program or traditional inpatient care, and the study will compare these approaches to find the best way to support youth in crisis. Families should know that the study involves regular evaluations and close support from hospital staff but does not include any treatments that are experimental or unproven.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Youth between the ages of 12 years 0 months and 17 years 6 months at time of consent
- • 2. Present to the Nationwide Children's Hospital (NCH) Psychiatric Crisis Department (PCD) or NCH Psychiatry Consult Liaison (CL) Service with suicidal ideation and/or behavior as the primary referral
- • 3. Be eligible for admission to both YCSU and APIU based on PCD or CL clinician's clinical judgement
- • 4. Patient and legal guardian must be willing to be admitted to either YCSU or APIU
- • 5. Youth obtains a score of ≥23 on the Concise Health Risk Tracking Self-Report (CHRT-SR)
- • 6. Youth resides with a primary caretaker who has legal authority to consent for participation in research
- • 7. Legal guardian must attend the PCD or CL evaluation
- Exclusion Criteria:
- • 1. Participants who are unable to understand study procedures (e.g., intellectual disability, actively psychotic)
- • 2. Inability to speak or read English adequately to understand and complete study consent and procedures
- • YCSU clinicians, PCD staff, and NCH-BH leaders will be invited to participate based on their roles in the system-of-care.
About Jennifer Hughes
Jennifer Hughes is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical pharmacology and extensive experience in trial design and management, she leads initiatives that focus on innovative therapies and evidence-based practices. Her collaborative approach fosters partnerships with research institutions and healthcare professionals, ensuring that trials are conducted with the highest standards of ethics and scientific rigor. Through her leadership, Jennifer aims to contribute to the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Patients applied
Trial Officials
Jennifer L Hughes
Principal Investigator
Nationwide Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported